目前，临床上伴有胃转移、腹膜转移和恶性腹水的晚期前列腺癌很少见，且最佳治疗方案尚不清楚。 本研究报道了一例伴有膀胱颈受累、盆腔淋巴结浸润的晚期前列腺癌患者，且肿瘤转移到骨、胃及腹膜等部位并伴 有恶性腹水。前列腺癌腹膜转移和恶性腹水的预后极差，其主要的治疗方法为症状支持、腹膜穿刺引流、内分泌治 疗和化疗。本研究通过报道一例伴有腹膜转移的晚期前列腺癌病例及回顾相关文献，为伴有恶性腹水的转移性前列 腺癌临床研究提供参考借鉴。

At present, clinically advanced prostate cancer with gastric metastasis, peritoneal metastasis and malignant ascites is rare, and the optimal treatment is unclear. This study reported a case of advanced prostate cancer with bladder neck involvement, pelvic lymph node invasion, and metastasis to bone, stomach, peritoneum with malignant ascites. The prognosis of prostate cancer with peritoneal metastasis and malignant ascites is extremely poor, and the main treatment methods are symptomatic support, peritoneal puncture and drainage, endocrine therapy and chemotherapy. Herein, through a case report of advanced prostate cancer with peritoneal metastasis and the review of relevant literatures, a case of advanced prostate cancer with peritoneal metastasis was reported and relevant literature was reviewed to provide reference for clinical research of metastatic prostate cancer with malignant ascites.

2021-07-12  录用日期：2021-11-10 

Received Date: 2021-07-12  Accepted Date: 2021-11-10 

基金项目：电子科技大学·四川省人民医院“医工交叉联合基金”（ZYGX2021YGLH011） 

Foundation Item: General Program of Medical Engineering Cross of Sichuan Provincial People’s Hospital & University of Electronic Science and Technology of China(ZYGX2021YGLH011) 

通讯作者：王东，Email:wangdong_robot@163.com 

Corresponding Author: WANG Dong, Email: wangdong_robot@163.com 

引用格式：任尚青，欧勇，李安，等 . 转移性前列腺癌伴恶性腹水一例报道 [J]. 机器人外科学杂志（中英文），2022，3（2）： 132-139. 

Citation: REN S Q, OU Y, LI A, et al. Metastatic prostate cancer with malignant ascites: a case report[J]. Chinese Journal of Robotic Surgery, 2022, 3(2):132-139. 

注：任尚青，欧勇为共同第一作者 

Co-first Author: REN Shangqing, OU Yong

[1] Salim E I, Magid A D, Farara K M, et al. Antitumoral and antioxidant potential of egyptian propolis against the pc3 prostate cancer cell line [J]. Asian PacJ Cancer Prey, 2015, 16(17):7641-7651. 

[2] Center M M, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates [J]. Eur Urol, 2012, 61(6):1079-1092. 

[3] Brawley O W, Gansler T. Introducing the 2010 american cancer society prostate cancer screening guideline [J]. CA Cancer J Clin, 2010, 60(2):68-69. 

[4] Chen W, Zheng R, Baade P D, et al. Cancer Statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132. 

[5] Arnheim F K. Carcinoma of the prostate: a study of the post-mortem findings in one hundred and seventy-six cases [J]. J Urol, 1948, 60(4):599-603. 

[6] Bubendorf L, Schöpfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1589 patients [J]. Hum Pathol, 2000, 31(5):578-583. 

[7] Rapoport A H, Omenn G S. Dermatomyositis and malignant effusions: rare manifestation of cancer [J]. J Urol, 1968, 100(2): 183-187. 

[8] Megalli M R, Gursel E O, Veenema R J. Ascites as an unusual presentation of carcinoma of the prostate [J]. J Urol, 1973, 110(2):232-234. 

[9] Beigel Y, Zelikovski A, Shimoni S, et al. Chylous ascites as a presenting sign of prostate adenocarcinoma [J]. Lymphology, 1990, 23(4):183-186. 

[10] Disdier P, Harle J R, Swiader L,et al. Ascites with cachexia revealing prostatic carcinoma[J]. Presse Med, 1990, 19(5):220. 

[11] Catton P A, Hartwick R W, Srigley J R. Prostate cancer presenting with malignant ascites: signet-ring cell variant of prostate adenocarcinoma [J]. Urology, 1992, 39(5):495-497. 

[12] Saif M W, Figg W D, Hewitt S, et al. Malignant ascites as only manifestation of metastatic prostate cancer [J]. Prostate Cancer Prostatic Dis, 1999, 2(5/6):290-293. 

[13] Tsai J Y, Ling M, Chang V T, et al. Hemorrhagic ascites: an unusual manifestation of prostate carcinoma [J]. Am J Med, 2001, 111(3):245-246. 

[14] Amin R. Chylous ascites from prostatic adenocarcinoma [J]. Urology, 2002, 59(5):773. 

[15] Kehinde E O, Abdeen S M, Al-Hunayan A, et al. Prostate cancer metastatic to the omentum [J]. Scand J Urol Nephrol, 2002, 36(3):225-227. 

[16] Lapoile E, Bellaïche G, Choudat L, et al. Ascites associated with prostate cancer metastases:an unusual localization [J]. Gastroenterol Clin Biol, 2004, 28(1): 92-94. 

[17] Appalaneni V, Yellinedi S, Baumann M A. Diagnosis of malignant ascites in prostate cancer by measurem Jakse Gent of prostate specific antigen [J]. Am J Med Sci, 2004, 327(5):262-263. 

[18] Brehmer B, Makris A, Wellmann A. Solitary peritoneal carcinomatosis in prostate cancer [J]. Actuelle Urol, 2007, 38(5):408-409. 

[19] Madaan S, Palit V, Gudgeon P, et al. Omental metastasis with malignant ascites: an unusual manifestation of prostatic adenocarcinoma [J]. Can Urol Assoc J, 2007, 1(3):288-290. 

[20] Zagouri F, Papaefthimiou M, Chalazonitis A N, et al.Prostate cancer with metastasis to the omentum and massive ascites: a rare manifestation of a common disease [J]. Onkologie, 2009, 32(12):758-761. 

[21] Benedict S P, Ahuja M, Mammen K J. Hormone refractory carcinoma of prostate with peritoneal metastases and malignant ascites without skeletal involvement: a case report and review of literature [J]. Indian J Urol, 2010, 26(2): 287-288. 

[22] Ani I, Colstaldi M, Abouassaly R. Metastatic prostate cancer with malignant ascites: a case report and literature review [J]. Can Urol Assoc J, 2013, 7(3-4): E248-E250. 

[23] Petrakis D, Pentheroudakis G, Kamina S, et al. An unusual presentation of a patient with advanced prostate cancer, massive ascites and peritoneal metastasis: case report and literature review [J]. J Adv Res, 2015, 6(3):517-521. 

[24] Shimizu Y, Kanamaru S, Ito N, et al. Simultaneous chylothorax and chylous ascites in a patient with castrationresistant prostate cancer after docetaxel chemotherapy: an unusual manifestation [J]. Int J Urol, 2015, 22(6): 614. 

[25] Papadatos S S, Bazoukis G, Deligiannis G, et al. Malignant ascites due to prostatic adenocarcinoma: an extremely rare manifestation of a common disease [J]. J Clin Diagn Res, 2016, 10(11): OL01. 

[26] Christoph F, Grünbaum M, Wolkers F, et al. Prostate cancer metastatic to the stomach [J]. Urology, 2004, 63(4): 778-779. 

[27] Ben-Izhak O, Lichtig C. Signet-ring cell carcinoma of the prostate mimicking primary gastric carcinoma [J]. J Clin Pathol, 1992, 45(5): 452-454. 

[28] Holderman W H, Jacques J M, Blackstone M O, et al. Prostate cancer metastatic to the stomach: clinical aspects and endoscopic diagnosis [J]. J Clin Gastroenterol, 1992, 14(3):251-254. 

[29] Green L K. Hematogenous metastases to the stomach. A review of 67 cases [J]. Cancer, 1990, 65(7): 1596-1600. 

[30] Oda I, Kondo H, Yamao T, et al. Metastatic tumors to the stomach: analysis of 54 patients diagnosed at endoscopy and 347 autopsy cases [J]. Endoscopy, 2001, 33(6): 507-510. 

[31] Kato M, Hirakawa A, Kobayashi Y Ms, et al. The influence of the presence of intraductal carcinoma of the prostate on the grade group system’s prognostic performance [J]. Prostate, 2019, 79(10):1065-1070. 

[32] Kemp C. Metastatic spread and common symptoms. Part six: Advanced cancer of the pancreas, prostate, stomach, and uterus [J]. Am J Hosp Palliat Care, 1999, 16(5):673-681. 

[33] Aoyama Y, Wato M, Colvin M, et al. A case of metastatic prostate cancer with gastric metastases and high serum CEA [J]. Nihon Shokakibyo Gakkai Zasshi, 2018, 115(9):804-810. 

[34] Onitilo A A, Engel J M, Resnick J M. Prostate carcinoma metastatic to the stomach: report of two cases and review of the literature [J]. Clin Med Res, 2010,8(1):18-21. 

[35] Broghamer W L Jr, Richardson M E, Faurest S, et al. PAP immunoperoxidase staining of cytologically positive effusions associate with adenocarcinoma of the prostate and neoplasms of undetermined origin [J]. Acta Cytol, 1985, 29(3):272-278. 

[36] Megalli M R, Gursel E O, Veenema R J. Ascites as an unusual presentation of carcinoma of the prostate [J]. J Urol, 1973, 110(2):232-234.